- Active Substance: Vorapaxar
- Name: ZONTIVITY™
- Therapeutic area: Reduction of thrombotic cardiovascular events
- Pharmaceutical company: Merck & Company Inc.
- Publication of final assessment: 17.06.2015
- Title: Vorapaxar for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
- Author/Co-Author: HAS (France), MoH Slovak Republic (Slovakia)
- Dedicated Reviewers: AOTMiT (Poland), SNHTA (Switzerland), AQUAS (Spain), HVB (Austria), SMC (Scotland), ZIN (Netherlands)
G-BA assessment not available
Reason: The marketing authorisation for Vorapaxar has been withdrawn at the request of the marketing authorisation holder.